Axillary Node Metastases of Medullary Thyroid Cancer: A Hallmark of
                    Terminal Disease

Andreas Machens; Kerstin Lorenz; Frank Weber; Henning Dralle

doi:10.1055/a-2172-9263

Hormone and Metabolic Research, Table of Contents

Horm Metab Res 2024; 56(06): 429-434
DOI: 10.1055/a-2172-9263

Original Article: Endocrine Care

Axillary Node Metastases of Medullary Thyroid Cancer: A Hallmark of Terminal Disease

Andreas Machens

¹Department of Visceral, Vascular and Endocrine Surgery, Martin Luther University of Halle-Wittenberg Faculty of Medicine, Halle, Germany

,

Kerstin Lorenz

¹Department of Visceral, Vascular and Endocrine Surgery, Martin Luther University of Halle-Wittenberg Faculty of Medicine, Halle, Germany

,

Frank Weber

²Department of General, Visceral and Transplantation Surgery, Division of Endocrine Surgery, University of Duisburg-Essen, Faculty of Medicine, Essen, Germany

,

Henning Dralle

²Department of General, Visceral and Transplantation Surgery, Division of Endocrine Surgery, University of Duisburg-Essen, Faculty of Medicine, Essen, Germany

› Author Affiliations

Abstract

Little is known about axillary node metastasis of medullary thyroid cancer (MTC). To address this, a comparative study of patients with and without axillary node metastases of MTC was conducted. Among 1215 consecutive patients with MTC, 482 patients had node-negative MTC and 733 patients node-positive MTC. Among the 733 patients with node-positive MTC, 4 patients (0.5%) had axillary node metastases, all of which were ipsilateral. Patients with axillary node metastases had 5.7–6.9-fold more node metastases removed, both at the authors’ institution (medians of 34.5 vs. 5 metastases; p=0.011) and in total (medians of 57 vs. 10 metastases; p=0.013), developed more frequently distant metastases (3 of 4 vs. 178 of 729 patients, or 75 vs. 24%; p=0.049), specifically to bone (2 of 4 vs. 67 of 729 patients, or 50 vs. 9%; p=0.046) and brain (1 of 4 vs. 4 of 729 patients, or 25 vs. 0.5%; p=0.027), and more often succumbed to cancer-specific death (3 of 4 vs. 52 of 729 patients, or 75 vs. 14%; p=0.005). Altogether, patients with axillary node metastases revealed 4–8-fold more node metastases in the ipsilateral lateral neck (medians of 11 vs. 3 metastases; p=0.021) and in the ipsilateral central neck (medians of 8 vs. 1 metastases; p=0.079) patients without axillary node metastases. Cancer-specific survival of patients with vs. patients without axillary node metastases of MTC was significantly shorter (means of 41 vs. 224 months; plog-rank<0.001). These findings show that patients with axillary node metastases of MTC have massive metastatic dissemination with poor survival.

Key words

medullary thyroid carcinoma - distant metastasis - neck node metastases - mediastinal node metastases - axillary node metastases

Full Text

References

References
1 Machens A, Holzhausen HJ, Dralle H. Contralateral cervical and mediastinal lymph node metastasis in medullary thyroid cancer: systemic disease?. Surgery 2006; 139: 28-32
2 Machens A, Hauptmann S, Dralle H. Prediction of lateral lymph node metastases in medullary thyroid cancer. Br J Surg 2008; 95: 586-591
3 Machens A, Holzhausen HJ, Dralle H. Prediction of mediastinal lymph node metastasis in medullary thyroid carcinoma. Br J Surg 2004; 91: 709-712
4 Machens A, Dralle H. Prognostic impact of N staging in 715 medullary thyroid cancer patients: proposal for a revised staging system. Ann Surg 2013; 257: 323-329
5 Machens A, Lorenz K, Dralle H. Prediction of biochemical cure in patients with medullary thyroid cancer. Br J Surg 2020; 107: 695-704
6 Ozdemir M, Makay O, Simsir I. et al. Medullary carcinoma of the thyroid with axillary metastasis: a case report. Int Surg 2015; 100: 390-393
7 Cummings AL, Goldfarb M. Thyroid carcinoma metastases to axillary lymph nodes: report of two rare cases of papillary and medullary thyroid carcinoma and literature review. Endocr Pract 2014; 20: e34-e37
8 Rasihashemi SZ, Azhough R, Ramouz A. Axillary lymph node metastasis in medullary thyroid carcinoma: a case report. Iran J Otorhinolaryngol 2017; 29: 295-297
9 Wells SA, Asa SL, Dralle H. et al. American Thyroid Association guidelines task force on medullary thyroid carcinoma. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 2015; 25: 567-610
10 Machens A, Dralle H. Biomarker-based risk stratification for previously untreated medullary thyroid cancer. J Clin Endocrinol Metab 2010; 95: 2655-2663
11 DeLellis RA, Lloyd RV, Heitz PU. et al. Classification of tumours of endocrine organs. World Health Organisation. 2017
12 Machens A, Dralle H. Breach of the thyroid capsule and lymph node capsule in node-positive papillary and medullary thyroid cancer: different biology. Eur J Surg Oncol 2015; 41: 766-772
13 Margraf RL, Crockett DK, Krautscheid PM. et al. Multiple endocrine neoplasia type 2 RET protooncogene database: repository of MEN2-associated RET sequence variation and reference for genotype/phenotype correlations. Hum Mutat 2009; 30: 548-556
14 Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481
15 Peto R, Pike MC, Armitage P. et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer 1977; 35: 1-39
16 Vogelstein B, Kinzler KW. The path to cancer – three strikes and you're out. N Engl J Med 2015; 373: 1895-1898
17 Mete O, Asa SL. Pathological definition and clinical significance of vascular invasion in thyroid carcinomas of follicular epithelial derivation. Mod Pathol 2011; 24: 1545-1552
18 Rajan N, Khanal T, Ringel MD. Progression and dormancy in metastatic thyroid cancer: concepts and clinical implications. Endocrine 2020; 70: 24-35
19 Machens A, Lorenz K, Weber F. et al. Exceptionality of distant metastasis in node-negative hereditary and sporadic medullary thyroid cancer: lessons learned. J Clin Endocrinol Metab 2021; 106: e2968-e2979
20 Esfandiari NH, Hughes DT, Yin H. et al. The effect of extent of surgery and number of lymph node metastases on overall survival in patients with medullary thyroid cancer. J Clin Endocrinol Metab 2014; 99: 448-454
21 Machens A, Dralle H. Surgical cure rates of sporadic medullary thyroid cancer in the era of calcitonin screening. Eur J Endocrinol 2016; 175: 219-228
22 Randle RW, Balentine CJ, Leverson GE. et al. Trends in the presentation, treatment, and survival of patients with medullary thyroid cancer over the past 30 years. Surgery 2017; 161: 137-146